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Abstract
Background Management of the axilla in breast cancer is
becoming increasingly conservative. Patients identified
with a low axillary nodal burden (two or fewer involved
nodes) at sentinel node biopsy (SNB) can avoid completion
axillary node clearance (cANC). ‘Fast track’ to ANC in
patients with involved nodes on pre-operative ultrasound
may be over-treating a subgroup of these patients with low
nodal burden, which would have precluded their need for
ANC. This systematic review assesses the proportion of
patients with involved nodes on pre-operative axillary
ultrasound, which would fit low axillary burden criteria.
Methods Meta-analysis of studies comparing axillary
burden of breast cancer patients identified as pre-operative
ultrasound negative versus positive was performed. The
primary outcome measure was the number of patients with
two or fewer involved nodes (macrometastases only).
Pooled odds ratio (OR), 95% confidence intervals (CIs),
means and probabilities of identifying two or fewer
involved nodes versus greater than two were calculated.
Results Six studies reported the axillary burden in 4271
patients who were either directed straight to ANC or cANC
after SNB. There was a significantly greater axillary burden
in the ultrasound positive versus negative groups (OR 5.95,
95% CI 5.80–6.11) with mean nodal retrieval values of 2.9
[standard error (SE) 0.2] and 1.6 (SE 0.2) nodes, respec-
tively. Cumulative probabilities identified 78.9% of ultra-
sound negative and 43.2% of ultrasound positive patients
possessed low axillary burden.
Conclusions Pre-operative ultrasound positive patients
have significantly higher axillary burden. However, nearly
half do fit the criteria of low axillary burden and could be
considered for omission of ANC.
Keywords Breast cancer  Axillary ultrasound  Sentinel
lymph node biopsy  Axillary node clearance  Axillary
burden
Introduction
The management of the axilla in breast cancer has been
increasingly progressing towards a more conservative
approach. This commenced with the omission of com-
pletion axillary node clearance (cANC) for isolated
tumour cells (ITCs) [1], before progressing to omitting it
for micrometastases [2] and then for low burden axillary
macrometastatic disease [3, 4] identified at sentinel node
biopsy (SNB)—in the presence of systemic therapy or
radiotherapy [3]. Pre-operative axillary ultrasound (with
core biopsy or fine needle aspiration) has become a
standard to stratify patients with high burden axillary
disease directly towards axillary clearance (ANC) and
omission of SNB, despite the fact that axillary ultrasound
was not required in any of the large randomized
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controlled trials (RCTs) of SNB [5–10]. Pre-operative
axillary ultrasound has traditionally not been able to
replace SNB because of its inferior sensitivity compared
to the latter [11, 12]. Therefore, the identification of
axillary disease on ultrasound is considered a prognostic
indicator of higher axillary burden requiring ‘fast track’ to
ANC and omission of SNB [13]. However, the lack of
clear criteria to stage the axilla and inter-personal varia-
tion in the performance of ultrasound means that there
potentially is a risk in the modern era of overtreatment of
the axilla in a certain group of patients who may have
fitted the category of low axillary burden (two or fewer
involved nodes with macrometastases) on SNB. The aim
of this meta-analysis is to determine the proportion of
patients directed to ‘fast track’ ANC who are found to
subsequently possess low axillary burden on histopathol-
ogy and consequently could have potentially avoided
ANC.
Methods
Study selection
A systematic review of the literature was performed using
MEDLINE, PubMed, Embase and Cochrane Library
databases to identify all articles evaluating the
histopathology of axillary specimens for metastatic nodal
burden after ANC in breast cancer. The search terms used
were: SNB and axillary ultrasound and axillary lymph
node clearance and axillary lymph node dissection and
breast cancer. Studies were restricted to those published
in the English language and performed in humans. The
related articles function was used to broaden the search,
and all abstracts, studies and citations obtained were
reviewed. References of the acquired articles were also
searched by hand. The last search was conducted on 1st
February 2017.
Inclusion criteria
Studies were included if they satisfied the following
eligibility criteria: performance of a comparison of the
histological metastatic axillary nodal burden at ANC
between breast cancer patients ‘fast tracked’ to ANC
[due to a positive pre-operative axillary ultrasound scan
(US) with core biopsy or fine needle aspiration] and
those with clinically and radiologically negative axillae
who were directed to SNB before undergoing cANC for
macrometastatic disease; quantified the resultant axillary
nodal burden at ANC in terms of 0–2 nodes and greater
than 2 nodes (‘low’ and ‘high’ axillary burden,
respectively); a satisfactory quality assessment score
attained (4 of 6 or greater) and written in the English
language.
Exclusion criteria
Studies that failed to fulfil the inclusion criteria or studies
in which the outcomes of interest were not reported were
excluded. Other exclusion criteria included: full text not
available, review article, letter to the editor, editorial
report, case report, duplicate publication, abstract.
Data extraction
Data were extracted from selected studies using a data
extraction form, which included information on: publica-
tion details; study design; number of patients; number of
axillary US positive patients—with positive core biopsy or
fine needle aspiration—and their nodal burden at ANC;
number of axillary US negative and SNB positive patients
and their nodal burden at ANC. The quality of cohort
studies was assessed according to the recommendations of
the Strengthening the Reporting of Observational studies in
Epidemiology (STROBE) statement [14] and six items of
the STROBE statement were considered relevant for
quality evaluation. Two-reviewers extracted data from
included studies independently. Comparison of the data
extraction and quality score was performed, and discrep-
ancies were resolved by consensus.
Statistical analysis
All extracted data were tabulated and presented numeri-
cally in terms of patient numbers according to pre-oper-
ative axillary status and their subsequent allocation to
‘low’ (fewer than two macrometastases) or ‘high’ (greater
than two macrometastatic nodes) axillary burden. The
Mantel–Haenszel test (Cochran) [15] was used to deter-
mine the difference in axillary burden between the pre-
operative US positive and negative groups. The odds
ratios (ORs) and 95% confidence intervals (CIs) were
calculated. Means and probabilities of axillary nodal
burden were calculated by fitting a beta-binomial distri-
bution to the number of involved nodes using the method
of maximum likelihood.
Results
The detailed literature search resulted in six studies being
critically appraised for this review (Fig. 1) [16–21].
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Study characteristics
The studies were published between 2014 and 2016. They
comprised six cohort studies [16–21] of which all were
retrospectively conducted—three using prospectively col-
lected databases [17–19].
Study quality
The relevant items of the STROBE statement that were
used for quality assessment of included cohort studies are
shown (Table 1). The overall STROBE score ranged from
4 to 6. The methodology and reported data of all included
cohort studies were considered adequate.
Study outcomes
Clinically significant axillary burden
Six studies [16–21] comprising 4271 patients provided data
on the presence of ‘high’ versus ‘low’ axillary burden—on
histology at ANC—in patients ‘fast tracked’ to ANC after
positive axillary scanning (1437 patients) and who under-
went cANC after positive SNB (greater than two
Titles identified from database searches n = 1079
PubMed n = 1017
EMBASE n = 62
Cochrane Library n = 0
Duplicates excluded 
n = 137
Title and abstract screened n = 942
Excluded based on title and abstract 
n = 863
Full-text articles assessed for eligibility n = 79
Excluded according to inclusion 
criteria n = 73
Included in review n = 6
Fig. 1 Selection of articles for review
Table 1 Study quality assessment of cohort studies
References Study
objectives
Clear inclusion
criteria
Standardized
technique
Only proven
malignancy
Patient follow-up
reported
Withdrawals from study
reported
Barco et al. [16] Y Y Y Y N N
Boland et al. [17] Y Y Y Y N Y
Boone et al. [18] Y Y Y Y N N
Moorman et al.
[20]
Y Y Y Y N N
Caudle et al. [19] Y Y Y Y N N
Verheuvel et al.
[21]
Y Y Y Y Y N
Study quality was assessed according to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement
Y yes, N no
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macrometastases; Table 2). There was significantly
greater ‘high axillary burden’ identified in the ultrasound
positive versus negative group (OR 5.95, 95% CI
5.80–6.11) and is graphically represented by the 95% CIs
for the probabilities of two or fewer involved nodes in
these two groups (Fig. 2). The beta-binomial model pro-
vided a mean number of macrometastatically involved
nodes excised at ANC of 2.9 [standard error (SE) 0.2] and
1.6 (SE 0.2) for the US positive and negative groups,
respectively. The beta-binomial fitted distribution of
expected involved nodes (Fig. 3) for the two groups
demonstrates the mode at one node for the US negative
(SNB positive) and two to three nodes for the US positive
group. The cumulative probabilities identify that 78.9% of
US negative patients have two or fewer involved nodes
compared to 43.2% of US positive patients.
Table 2 Study characteristics and outcomes of axillary nodal burden in pre-operative ultrasound positive and negative groups
References Study type Total number of
patients
Pre-operative US positive axilla Pre-operative US negative axilla (SNB
positive)
Number of
patients
B2 Nodes at
ANC
[2 Nodes at
ANC
Patient
numbers
B2 Nodes at
ANCb
[2 Nodes at
ANCb
Barco et al. [16] Retrospective
cohort
594a 282 136 146 312 248 64
Boland et al.
[17]
Retrospective
cohort
974 439 112 327 535 412 123
Boone et al.
[18]
Retrospective
cohort
633 199 70 129 434 353 81
Moorman et al.
[20]
Retrospective
cohort
1060 181 116 65 879 842 37
Verheuvel et al.
[21]
Retrospective
cohort
302 139 51 88 163 126 37
Caudle et al.
[19]
Retrospective
cohort
708 190 (149) 99 (82) 91 (67) 518 417 101
( ) Proportion of patients with one or two suspicious lymph nodes on ultrasound
a Selection of patient numbers according to those identified as node positive from the data
b Cumulative number of involved nodes identified—at sentinel node biopsy and completion axillary clearance
Barco et 
al.
Boland 
et al.
Boone 
et al.
Moorman 
et al.
Verheuvel 
et al.
Caudle 
et al.
Fig. 2 The 95% confidence
intervals for the probabilities of
identification of two or fewer
involved nodes on pre-operative
ultrasound negative and positive
patients
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Only one study [19] performed a quantification of the
number of suspicious nodes identified on axillary ultra-
sound. Caudle et al. [19] identified that 78% of pre-oper-
ative ultrasound positive patients had one or two suspicious
nodes identified. Of these patients 55% had two or fewer
involved nodes on histopathology at ANC. They were the
only authors to perform multivariate analysis of predictors
of high axillary burden within the ultrasound positive
group. They identified that there was a significant rela-
tionship between lobular histology and high axillary bur-
den (three or more involved nodes, OR 1.77; 95% CI
1.06–2.95) at ANC.
Discussion
The management of the axilla in breast cancer has seen the
emergence of surgical conservatism away from ANC in
view of its lack of disease-free and overall survival benefit
[4, 22, 23]. This has resulted in the increasing importance
of the quantification of axillary disease in order to differ-
entiate between ‘high’ and ‘low’ axillary burden. The
current criteria for this is based upon those established
within the ACOSOG Z0011 trial [4] and then formally
supported by the American Society of Clinical Oncologists
(ASCO) [24]. During the ACOSOG Z0011 [4] trial pre-
operative axillary ultrasound was not performed. This is
directly in conflict with mainstream practice, which directs
those patients with suspicious axillary findings on ultra-
sound to undergo tissue sampling by either core biopsy or
fine needle aspiration. Those patients identified to have
metastatic disease pre-operatively, are streamlined directly
to ANC. This means that out of those patients who have
metastatic axillary disease, one-third (Table 2) of them
would have undergone SNB rather than ‘fast track’ ANC if
they were part of the ACOSOG Z0011 trial and half of
these would have fit criteria of ‘low axillary burden’ and
been omitted ANC. This certainly is suggestive that the use
of pre-operative ultrasound is directing a greater number of
patients to ANC and denying them axillary preservation
than is otherwise necessary.
It has been established that axillary burden in those
patients with pre-operative positive ultrasound findings is
greater than in those that are negative. Van Wely et al. [13]
in their meta-analysis of ultrasound-guided biopsy for
determining axillary burden demonstrated that the number
of involved nodes was significantly higher in patients in
whom axillary metastases were identified by ultrasound-
guided biopsy (P\ 0.001). Unfortunately, due to the lim-
itations of the data available at the time, the authors were
only able to categorize axillary burden in the US positive
and negative groups to one to three and greater than three
nodes and were unable to segregate ITC, micro and mac-
rometastatic disease. This prevented the relevance of their
data to modern guidelines and the criteria for ‘low and high
axillary burden’ [24]. This meta-analysis supports the
finding of van Wely et al. [13] as we too found that there
was significantly higher axillary burden in the pre-opera-
tive positive US group compared to the negative one (OR
5.95, 95% CI 5.80–6.11). This was at the clinically relevant
threshold of two nodes or fewer and greater than two
nodes, in addition to only considering macrometastases.
Our meta-analysis also demonstrated that the mean number
of nodes expected to be retrieved in patients with a positive
Fig. 3 Estimated axillary
metastatic nodal distribution
according to pre-operative
ultrasound status from binomial
expansion of recorded data
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US is twice that of those with a negative US [3.0 vs. 1.6
(SE 0.2)]. It has also been shown that the mode distribution
of involved nodes is one and two to three for US negative
and positive patients, respectively. This clearly demon-
strates that axillary burden is higher in the US positive
group. It is logical, as the sensitivity of US has been con-
sistently shown to be inferior to that of SNB for the
identification of metastatic disease [11, 12]. Therefore, for
disease to be visible to the radiologist one would expect
that it might be of greater quantity.
However, in an era of increasingly targeted and per-
sonalized therapy, it is not adequate to consider these data
purely within the context of ‘greater axillary burden’ pre-
sent in the US positive group. This meta-analysis identified
43% of US positive patients had two or fewer nodes con-
sistent with low axillary burden, which would allow them
to avoid ANC. This raises the question of how do we
prevent the overtreatment of this group? For the 43% of
patients receiving an unnecessary ANC, a possibility could
exist in avoiding the performance of pre-operative axillary
ultrasound. Such a technique would increase the patients
directed to SNB rather than ‘fast track’ ANC by approxi-
mately one-third and of this one-third, half would avoid
cANC on the basis of subsequent SNB histology. The only
patients fast tracked to ANC would be those patients with
palpable axillary lymphadenopathy—consistent with the
protocols of RCTs of SNB [5–10]. This approach would
make a contribution, but may give the appearance of a
regressive step and could be detrimental in patients with a
high body mass index where axillary ultrasound has been
demonstrated to possess great accuracy [25]. It is known
that this approach to omitting pre-operative axillary ultra-
sound has already been adopted in certain academic breast
units within the USA. However, published data on the
outcomes of this practice are not currently available and
the American Society of Breast Surgeons [26] still advo-
cates pre-operative axillary ultrasound in the presence of
diagnosed breast cancer. Another approach would be to
improve quantification of axillary US findings—which is
difficult with the inter-personal variation associated with
the performance of US. However, the impetus should be
placed upon the radiologist to quantify the number of
suspicious nodes visible. The suitable threshold to be used
for this would have to be ascertained through further
clinical evaluation, as it cannot be assumed to extrapolate
to two or fewer visible nodes on US. Only the study by
Caudle et al. [19] demonstrated that by using a threshold of
two suspicious nodes or fewer that the number of patients
with two or fewer involved nodes at ANC was 55%. If a
threshold of one suspicious node only was applied this
percentage would inevitably increase. Therefore, it is likely
that the cut off on axillary ultrasound should be one to two
suspicious nodes but confirmation of this should form the
basis of future research—as such data are minimal within
the literature. In addition to quantification, the suspicious
nodes could also be marked pre-operatively at US using
clips, which could then allow targeted intra-operative
excision. This technique has successfully reduced the false
negative rate at SNB within the neo-adjuvant chemother-
apy setting to under 2% [27]. It has to be stressed that
unless ultrasound evolves and is approached in this man-
ner, it is likely to become disadvantageous and its role
increasingly questionable.
Axillary radiotherapy could play a role in management
but it must be remembered that the AMAROS trial [3] did
not use pre-operative axillary ultrasound and excluded
patients on the basis of palpable lymphadenopathy—con-
sistent with the original trials of SNB [5–10] and ACOSOG
Z0011 [23]. Whilst there was no threshold limit of axillary
burden to exclude patients from randomization, only 5% of
patients in the radiotherapy and ANC arms had a burden of
three or more involved nodes at SNB. It is also important to
note that only 60% of involved nodal burden in each arm
consisted of macrometastases. Axillary radiotherapy cer-
tainly could be considered a therapeutic option for the 43%
of patients who fit the low axillary burden criteria (two or
fewer involved nodes) despite a histologically involved
axilla on pre-operative US. However, as a blanket treat-
ment of patients with burden greater than two nodes, it
would be unproven.
The issue of patients undergoing mastectomy and their
axillary burden was not addressed by the ACOSOG Z0011
trial [23]. Within the included trials of this meta-analysis,
mastectomy rates varied between 32 and 65% [19, 21].
Whilst it may be assumed that the ACOSOG Z0011 criteria
could be extrapolated to mastectomy patients, it would
mean that patients who would have avoided chest wall
radiotherapy in the event of ANC may become committed
to it if no further intervention is performed to the axilla.
This would be the only safe option in the absence of further
clinical trial data.
It is also acknowledged that whilst attempting to avoid
ANC in the identified cohort of 43%, it means that the
remaining 57% of patients, who do not fit the criteria of
‘low axillary burden’ will have to undergo two operations
with the associated additional exposure to a general
anaesthetic and potential financial implications—although
the latter could be offset by the saving in the ‘low axillary
burden’ group avoiding ANC. In other aspects such as the
administration of primary chemotherapy, this approach
would not detrimentally influence patient management and
would allow accurate axillary staging with SNB post-
chemotherapy, especially if ‘clipping of suspicious nodes’
is performed [27, 28].
The use of other imaging modalities should be consid-
ered to complement physical examination, particularly in
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obese patients where such clinical assessment is very
challenging. Magnetic resonance imaging (MRI) has failed
in mainstream uptake for axillary staging in breast cancer
due to its high false positive rate when compared to SNB
(6.3 vs. 0.2%, respectively) [29]. This is a significant
limitation when a key aim of modern axillary management
is to avoid overtreatment of the axilla or if MRI is being
used to identify ‘high axillary burden’ and ‘fast track’ to
ANC—avoiding SNB altogether. A systematic review of
positron emission tomography (PET) for the assessment of
axillary lymph node status in early breast cancer found that
across 26 studies evaluating PET or PET/CT, the mean
sensitivity and specificity was 63 and 94%, respectively
[30]. Clearly, these areas of research should continue to be
explored but will also face challenges within the financial
constraints of public healthcare systems.
It must be remembered that such advancements are not
only targeted at reducing the 43% of patients with positive
US who have an unnecessary ANC but also the 79% of US
negative patients with low axillary burden found on SNB
who could potentially have avoided SNB. The case of the
latter may well be addressed by ongoing current research
[31] but the 43% provide a greater long-term area of
concern. Only the article by Caudle et al. [19] attempted to
identify discriminating factors for high axillary burden
within the ultrasound positive group. On multivariate
analysis they identified lobular histology as a risk factor
(OR 1.77; 95% CI 1.06–2.95). Urgent analysis of further
risk factors within this group, are warranted to prevent
overtreatment and could potentially involve the use of
molecular profiling. In the void of advanced imaging
modalities, quantification of axillary ultrasound is essential
in non-palpable axillary disease. Within this meta-analysis,
none of the included articles [16–21] provided any details
on the quantification of axillary disease on US, highlighting
that this is clearly an area, which needs to be improved
upon. It would be suggested that the number of abnormal
axillary lymph nodes should be clearly stated by the con-
ducting radiologist. Those with inconsistent ultrasound
findings or a single abnormal node should be offered SNB
without axillary ultrasound directed biopsy. Those patients
with more than one abnormal node or those with an
abnormal node who are about to commence primary
chemotherapy, should be considered for biopsy and clip-
ping of the node(s). Further studies are needed to refine the
technique of clipping the node and SNB with removal of
the clipped node. The only other current option would be to
avoid axillary ultrasound altogether to avoid overtreatment.
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